Locations:
Search IconSearch
October 5, 2021/Pediatrics/Cardiology

Surgical Management of Symptomatic Neonates with Tetralogy of Fallot

Options have comparable survival rates, but other factors should drive the decision.

21-CHP-2180858-Hero-650×450

About 10% of neonates born with tetralogy of Fallot (TOF) become symptomatic and require urgent intervention. The two choices are early primary surgical repair (EPSR), in which the ventricular septal defect is closed and the right ventricular (RV) outflow obstruction is relieved, and a two-staged palliative (SP) approach, in which an interval shunt is used to secure a reliable source of pulmonary blood until the infant is larger and better able to withstand surgery. However, the ideal approach remains controversial.

Advertisement

Cleveland Clinic is a non-profit academic medical center. Advertising on our site helps support our mission. We do not endorse non-Cleveland Clinic products or services. Policy

“There are advantages and disadvantages to both approaches,” says Cleveland Clinic pediatric critical care specialist Mohammed Hamzah, MD. “EPSR for TOF ideally restores a normal cardiovascular anatomy and physiology, resolves the chronic cyanosis and promotes normal neurological development during a critical time of its rapid development in early infancy. It also may restore normal development of pulmonary vasculature and alveologensis in patients with diminished pulmonary perfusion,” he says.

“In symptomatic infants with hypercyanotic spells, a two-stage approach with an interval shunt ideally secures a reliable source of pulmonary blood flow. It also avoids potential organ damage from neonatal open-heart surgery and allows for time to attain somatic growth and organ maturity prior to the utilization of cardiopulmonary bypass in the second stage,” he says.

Taking a deep dive

In hopes of determining whether one strategy may be preferable, Dr. Hamzah and colleagues conducted a retrospective study of neonates ages 28 days and younger with TOF entered in the U.S. National Inpatient Sample (NIS) database between 2000 and 2018.

The patients were divided into two categories: asymptomatic infants and infants with severe symptoms necessitating immediate surgical intervention. They were further identified as having undergone EPSR, SP or no procedure.

The findings of this study were presented as an abstract at the Pediatric Academic Societies meeting in April 2021.

Similarities and differences

A total of 29,292 neonates with TOF were identified. Of these, 1,726 had undergone EPSR, 4,363 had undergone SP and 23,203 had no intervention as neonates.

Advertisement

Mortality rates in the EPSR and SP groups were found to be similar (8.0% vs. 7.4%).

Compared with EPSR, patients in the SP group had more comorbidities in the form of chromosomal anomalies (13.2% vs. 7.8%), prematurity (15.1% vs. 10.4%) and low body weight (15.4% vs.10.3%).

Compared with SP, EPSR patients had higher rates of ECMO utilization (4.6% vs. 3.5%), higher median length of stay (25 days vs. 19 days) and significantly higher median cost of hospitalization ($312,405 vs. $191,863).

The researchers also identified 15,946 patients with TOF who had undergone surgical repair after their first 28 days of life. These patients had significantly lower mortality than those who had undergone EPSR (1.5% vs. 8.0%).

“Several studies assessing the relationship between age of TOF surgical repair and RV hypertrophy remodeling showed that earlier repair was associated with a hastened course of RV remodeling and regression of RV hypertrophy, compared with late surgical repair,” says Dr. Hamzah. “If we include the cumulative morbidity and resource utilization associated with a two-staged repair, EPSR could be proven the better strategy in symptomatic neonates with TOF.”

The surgeon’s point of view

Hani Najm, MD, Chair of Pediatric and Congenital Heart Surgery at Cleveland Clinic, has performed several hundred EPSR cases. He agrees with the findings of this study.

“The goal should be to have a surviving patient with a good repair. This becomes center specific. If this can be achieved with SP, fine. Some centers defer to SP because they either have difficulty managing neonatal surgery or they have a bias for palliation he says. “Some centers have the option of doing both procedures and choose SP if it is reasonable. However, it is well known that palliative procedures requires repeated surgeries, continuation of cyanosis and possibly distortion of the pulmonary artery when the shunt is placed, necessitating more surgeries or stenting even after the final repair.”

Advertisement

In reality, says Dr. Najm, multiple factors must be considered when deciding on the better approach for a symptomatic neonate. Early and late outcome has to be in consideration. I believe every patient presents with a set of problems that the treating team should decide on the approach..

“Additionally, it’s very important to take into account factors not related to TOF itself, including low birth weight, brain hemorrhages and gastrointestinal tract anomalies, all of which are common in symptomatic neonates with TOF,” he says.

Advertisement

Related Articles

Adolescent patient sitting on hospital bed while provider uses stethoscope
October 3, 2024/Pediatrics/Cardiology
1 in 10 Children Will Experience Recurrent Rejection Following Heart Transplant

Results from a large registry study provide an updated picture of recurrent rejection

Surgeon holding VAD in the operating room
August 12, 2024/Pediatrics/Cardiology
Does Center Volume Impact VAD Implant Outcomes in Children?

Study explores center volume and outcomes using the STS-Pedimacs database

Surgeon looking down in the operating room
July 31, 2024/Pediatrics/Cardiology
Perioperative Electroencephalogram Predicts Neurodevelopmental Outcomes in Infants With Congenital Heart Disease

Pre and post-surgical CEEG in infants undergoing congenital heart surgery offers the potential for minimizing long-term neurodevelopmental injury

Physician holding wearable biosensor device talking to colleague
July 17, 2024/Pediatrics/Cardiology
Fostering the Future of Wearable Biosensors for Congenital Heart Disease

Science advisory examines challenges, ethical considerations and future directions

Physician caring for infant on exam table
July 9, 2024/Pediatrics/Cardiology
More Questions Remain About the Role of Statins in Pediatric Heart Transplant

Large registry study explores association between statin use and long-term outcomes

Doctor uses stethoscope on teen boy
June 12, 2024/Pediatrics/Cardiology
Experts Define Care and Research Gaps for Chronic Heart Failure in Children and Adolescent Patients With Congenital Heart Disease

Panel proposes staging and treatment protocols that support harmonized evaluation and management of heart failure in patients with congenital heart disease

3D reconstruction of aortic root in congenital heart disease
May 16, 2024/Pediatrics/Cardiology
Personalized Surgical Planning for Aortic-Valve Sparing Operations in Children and Young Adults

Center uses advanced imaging techniques to optimize valve repair strategies

Ad